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Background: Amyloid-β precursor protein (APP) is a highly conserved single transmembrane protein that has been
linked to Alzheimer disease. Recently, the increased expression of APP in multiple types of cancers has been
reported where it has significant correlation with the cancer cell proliferation. However, the function of APP in the
pathogenesis of breast cancer has not previously been determined. In this study, we studied the pathological role
of APP in breast cancer and revealed its potential mechanism.
Methods: The expression level of APP in multiple breast cancer cell lines was measured by Western blot analysis and
the breast cancer tissue microarray was utilized to analyze the expression pattern of APP in human patient specimens.
To interrogate the functional role of APP in cell growth and apoptosis, the effect of APP knockdown in MDA-MB-231 cells
were analyzed. Specifically, multiple signal transduction pathways and functional alterations linked to cell survival and
motility were examined in in vivo animal model as well as in vitro cell culture with the manipulation of APP expression.
Results: We found that the expression of APP is increased in mouse and human breast cancer cell lines, especially in
the cell line possessing higher metastatic potential. Moreover, the analysis of human breast cancer tissues revealed a
significant correlation between the level of APP and tumor development. Knockdown of APP (APP-kd) in breast cancer
cells caused the retardation of cell growth in vitro and in vivo, with both the induction of p27kip1 and caspase-3-mediated
apoptosis. APP-kd cells also had higher sensitivity to treatment of chemotherapeutic agents, TRAIL and 5-FU. Such
anti-tumorigenic effects shown in the APP-kd cells partially came from reduced pro-survival AKT activation in response to
IGF-1, leading to activation of key signaling regulators for cell growth, survival, and pro-apoptotic events such as GSK3-β
and FOXO1. Notably, knock-down of APP in metastatic breast cancer cells limited cell migration and invasion ability upon
stimulation of IGF-1.
Conclusion: The present data strongly suggest that the increase of APP expression is causally linked to tumorigenicity as
well as invasion of aggressive breast cancer and, therefore, the targeting of APP may be an effective therapy for breast
cancer.
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Amyloid-β precursor protein (APP) is a highly conserved
single transmembrane protein with a receptor-like struc-
ture and has been linked with Alzheimer disease [1,2]
while its normal physiological function is unclear. Several
APP isoforms derived from alternative splicing processes
have been reported and diverse products including soluble
APP (sAPP) or abnormal amyloid-β peptide through α-, β-,
or γ-secretase-mediated cleavage(s) are post-translationally
generated [3,4]. APP is ubiquitously expressed in a broad
spectrum of cell types including non-neuronal cells, while
the nature of APP has been mainly studied in neuronal
cells due to its pathological significance in Alzheimer dis-
ease. Several pathophysiological functions of APP have
been proposed such as its potential role in cell growth and
cell adherence [5-7]. It has been demonstrated that APP is
engaged in neuronal growth cone adhesion and plays a role
as an independently operating cell adhesion molecule for
binding to extracellular matrices such as laminin [6].
Specifically, it has been reported that APP is linked to pro-
liferation of thyroid epithelial cells and epidermal basal cell
proliferation [8-11] and, interestingly, the increased ex-
pression of APP in several types of cancers including pan-
creatic, lung, colon and breast cancer has been reported
[10-15]. These studies suggested that APP has growth-
promoting effect as an autocrine growth factor while the
underlying mechanism in the regulation of cellular signal-
ing and gene expression has not been fully explored. The
potential role of APP in cancer cell motility is also
supported by studies which show APP plays a role in
migration of neuronal precursor cells and neurite out-
growth [16,17].
In this study, we explored the pathological role of APP
in malignancy of breast cancer and its potential molecular
mechanism related with cell proliferation and metastasis.
Breast cancer is the most common cancer diagnosed
among women worldwide [18] and metastatic breast can-
cer is significantly correlated with poor prognosis and a
main cause of death while the underlying molecular
pathogenic mechanism still remains to be delineated. We
found that the expression level of APP is mechanistically
linked with tumorigenicity and malignancy of breast
cancer. APP knockdown (APP-kd) in breast cancer cells
reduced cell growth via p27kip1 induction, promoting
apoptosis, increasing sensitivity to therapeutic treatments,
and delayed cell migration and invasion ability upon
stimulation. These results suggest that targeting APP may
effectively suppress the growth and invasion of malignant
breast cancer cells.
Methods
Cell culture and reagents
MDA-MB-231 cells were grown in DMEM, and 67NR,
4T07, and 4T1 breast cancer cell lines were grown inRPMI supplemented with 10% (vol/vol) FBS, penicillin
(100 units/ml), and streptomycin (100 μg/ml; Invitrogen,
Rockville, MD). The four human breast cancer cell lines
MCF10A1 (M-I), MCF10AT1k.cl2 (M-II), MCF10CA1h
(M-III), and MCF10CA1a.cl1 (M-IV) were obtained from
Dr. Anita Roberts (NCI/NIH, Bethesda, MD). M-I, M-II,
M-III, and M-IV cells were grown in DMEM/F12 (Invitro-
gen, Carlsbad, CA) containing 5% horse serum (Invitrogen)
at 37°C with 5% CO2. M-I and M-II cells were supple-
mented additionally with 10 μg/ml insulin (Sigma, St.
Louis, MO), 20 ng/ml epidermal growth factor (Sigma), 0.5
μg/ml hydrocortisone (Sigma), and 100 ng/ml cholera
toxin (Sigma). Antibodies specific for APP (22C11) were
purchased from EMD Millipore; APP (4G8) from Covance.
Specific antibodies for p27(C-19) and p21 (F-5) were from
Santacruz and anti-β-actin (AC-15) was from Sigma. Anti-
bodies purchased from Cell Signaling were AKT (#9772),
pAKT Thr308 (#4056), pAKT Ser473 (#9271), pFOXO1
Thr24 (#9464), pGSK3 Ser9 (#9336), pp65 Ser536
(#3033), pERK1/2 (#9101), β-Catenin (#9562), PARP
(#9542), and cleaved Caspase-3 (#9661). Anti-survivin
antibody (AB8228) was purchased from Abcam. The anti-
CD44 antibody (#15675-1-AP) was from Proteintech
group and anti-GSK3b (KAP-ST002E) antibody was from
Stressgen.
Knockdown of human APP using lentiviral infection
system
Knockdown of human endogenous APP gene expression
was carried out using the lentivirus shRNA expression
system and experimental method as previously described
[19]. The target sequence of human APP (shAPP-5: 5’-
CCCTGTTCATTGTAAGCACTT, shAPP-7: 5’-GCAG
ACACAGACTATGCAGAT) or control luciferase was
used. In order to produce viral particles, the shRNA
constructs and virus packaging plasmids were trans-
fected into fresh 293T cells and then harvested the viral
supernatant and filtered through 0.45 μm syringe filter
prior to infection. Target cells were infected with virus
by spinning at 2000 rpm for 30 min. Semi-quantitative
RT-PCR and immunoblotting were carried out to meas-
ure knock-down efficiency.
Western blotting and RT-PCR
The cells were harvested and lysed in RIPA buffer. Equal
amounts of protein were loaded and separated in SDS-
PAGE gel and then transferred to PVDF membrane. The
blot was incubated in blocking solution (5% milk/TBST)
and then incubated with primary antibody followed by
incubation with secondary HRP conjugated antibody for 1
or 2 hours. The blot was washed 3 times for 5 minutes with
TBST between the incubations. Eventually, the change of
target protein expression was detected by conducting reac-
tion with Chemiluminescent Substrate (Thermo Scientific),
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the level of APP mRNA expression was performed with
the primers specific to human APP [20].
Detection of apoptotic cell population
MDA-MB-231 cells (5×104) freshly infected with shLuc,
shAPP-5, or shAPP-7 lentiviral particles were immedi-
ately seeded in 6-well plates. In order to detect early
apoptotic events, we employed Annexin V staining
method (eBioscience) which can detect phosphatidylser-
ine on the outer plasma membrane upon initiation of
apoptosis. Cell viability staining was carried out using
propidium iodide (PI) to identify early-stage apoptotic
cells. The FACS analysis was immediately followed after
staining the cells.
Cell growth assay
The control and APP-kd of MDA-MB-231cells (2×103)
were seeded in 6-well plate in triplicate and maintained
in normal growth medium. The sub-confluently growing
cells were counted using coulter counter (Beckman) at
day 2 and 4.
Wound-healing assay and cell invasion assay
To compare the cell motility, the MDA-MB-231 control
(shluc) or APP knockdown (shAPP-7) MDA-MB-231
cells were examined in wound healing assay. The conflu-
ently grown cells were wounded with 200 μl tips and
followed by either no treatment or treated with IGF-1
(25 ng/ml) for 18 hours in 0.1% serum containing
medium. Subsequently, cells were fixed with 2% parafor-
maldehyde and then stained with rapid 3 step staining
set (Richard-Allen Scientific) for clear visualization of
migrated cells. The initial wounded edges were marked
with dotted lines. Representative results from at least
three independent experiments are shown. Cell invasion
assays were performed by seeding cells in Boyden chamber
(BD Bioscience) coated with matrigel in serum-free
medium with or without IGF-1 (50 ng/ml) in the bottom
of each wells for 18 hours. The migrated cells were visual-
ized by staining and photographing under the microscope.
Xenograft mouse model
The breast cancer cells were seeded freshly prior to in-
jection. The control and shAPP MDA-MB-231 (1×106)
cells were prepared in the solution (1:1) of PBS and
growth factor-reduced matrigel and followed by injection
into athymic nude mice subcutaneously. Primary tumor
outgrowth was monitored every 4 days by taking measure-
ments of the tumor length (L) and width (W). Tumor vol-
ume was calculated as πLW2/6 [21]. The mice were
maintained up to 6 weeks and sacrificed for tumor exci-
sion. The tumor growth was compared to the counterpart
and imaged. All animal housing and procedures wereperformed in compliance with guidelines established by
the Institutional Animal Care and Use Committee at Case
Western Reserve University.
Immunohistochemistry
The breast cancer tissue array was purchased from US
Biomax (Cat# BRC961). For immunohistochemistry for
the APP detection, the tissue microarrays were hydrated
through two changes of xylene and descending ethanol
solutions for 10 min each, followed by a 30 min submer-
sion in 3% H2O2 and finally Tris-buffered saline (TBS).
The slides were incubated in 10% normal goat serum
(NGS) in TBS for 30 min and the primary antibody was
applied overnight. A monoclonal antibody specific to
APP, 22C11 (recognizing the N-terminal domain of full
length amyloid-β precursor protein; EMD Millipore,
1:250), was applied to the microarrays and then the
peroxidase-anti-peroxidase technique was employed and
developed with 3′-3’-diaminobenzidine (Dako).
Statistical analysis
Data are presented as means ± standard deviation.
Differences between the experimental groups were com-
pared with Student’s paired two tailed t-test. A p-value less
than 0.05 was considered statistically significant.
Results
The level of APP expression is linked to malignancy of
breast cancer cells
In order to investigate the correlation between APP expres-
sion and malignancy of breast cancer, the expression level
of APP was examined in a series of human and mouse
breast cancers with increasing malignancy. The four human
breast cancer cell lines MCF10A1 (M-I), MCF10AT1k.cl2
(M-II), MCF10CA1h (M-III), and MCF10CA1a.cl1 (M-IV)
were used in which M-I cells are spontaneously immor-
talized from normal breast epithelial cells whereas M-II, M-
III, and M-IV cells are derived from M-I cells transformed
with Ha-Ras oncogene [22,23]. M-III cells are a well-
differentiated tumor derived from M-II xenografts while
M-IV cells are a poorly differentiated metastatic tumor de-
rived from xenografts of M-II cells. In our analysis, the total
APP expression of both mature (upper band) and imma-
ture (lower band) forms was significantly elevated approxi-
mately 2 to 7-fold in MCF10A (M-II, -III, and -IV) cells
compared to M-I cells (Figure 1A). This positive correlation
between APP expression and malignancy was further con-
firmed in mouse breast cancer cells; 67NR, 4T07, and 4T1
cells which are derived from the same primary tumor [24].
67NR cells, which can form primary tumors without meta-
static ability, showed negligible APP expression whereas
highly tumorigenic 4T07 and metastatic 4T1 cells express
APP up to 8-fold (Figure 1B). These results suggest that
APP is functionally linked to the aggressiveness in breast
Figure 1 The elevated expression of APP engaged in breast cancer cell proliferation. (A) APP expression is detected by 22C11 mouse
monoclonal anti-APP antibody in human breast cancer cell lines and correlates with increasing malignancy. (+); a positive control of APP protein
overexpressed in neuronal cells. (B) The expression of APP is compared in mouse breast cancer cells with increasing metastatic potential. (C) APP
protein expression was present at a similar level in both M-IV and MDA-MB-231. Knock down of APP expression was verified in RT-PCR following
lentiviral infection encoding shAPP in MDA-MB-231. APP knockdown resulted in decreased expression of APP and soluble APP. The equal volume
of conditioned media was condensed by using Centricon and analyzed in Western blot. For the loading control, β-actin was uesd. (D) Cells (2x103)
were seeded in 6-well plate and cell numbers counted using coulter counter at day 2 and 4. (E) MDA-MB-231 cells were seeded at two different
numbers and the cell growth was compared by MTT assay. (F) MDA-MB-231 cells fixed and stained with propidium iodide (PI) were subjected to cell
cycle analysis by FACS.
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such as tumorigenic and metastatic ability.
Reduction of the expression of APP prevents cell growth
in MDA-MB-231 cells
We investigated the pathophysiological function of APP
by knocking it down using the shRNA targeting APP in
MDA-MB-231 malignant human breast cancer cells (Fig-
ure 1A). Both mRNA and protein expression of APP were
markedly reduced in APP-kd cells compared to control
cells (Figure 1C). APP protein expression of MDA-MB-
231 was comparable to that of M-IV cells while MDA-
MB-231, but not M-IV cells, showed fair amount of
soluble APP secretion that is known to enhance cell
growth and survival [25,26]. Next, we examined cell prolif-
eration in normal growth medium with 10% FBS in the
control (shluc) and APP-kd (shAPP) cells. Consistent with
our hypothesis, reduction of APP expression significantly
affected cell proliferation and viability (Figure 1D,E). To
confirm the effect of APP on cell growth further, we
performed FACS analysis to determine cell cycle phase.The cell cycle analysis showed that APP-kd cells were
arrested largely in G1 phase (45.2%) compared to control
(31.4%), but low percentage of APP-kd cells (19.4%) was
in S phase as compared to that of control cells (25.5%)
(Figure 1F). Retarded cell growth and G1 arrest of APP-kd
cells suggest that APP is likely engaged in expression of
cell cycle inhibitors working on G1 phase such as p27kip1
and p21cip1 [27,28].
APP enhances cell proliferation via regulation of p27kip1
To address whether APP regulates G1 phase cell cycle
inhibitors, the control and APP-kd cells grown in normal
growth medium were examined to compare p27kip1 and/
or p21cip1 expression of APP-kd cells to control. In our
analysis, the level of p27kip1 was dramatically induced in
APP-kd cells compared to control (Figure 2A and 2B).
However, p21cip1 expression was unchanged or slightly
affected by APP knockdown in multiple cell lines (M-I,
M-IV and MDA-MB-231) (Figure 2B and 2C) suggesting
that APP regulates cell cycle by modulating p27kip1
specifically.
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either a tumor suppressor or promoter because nuclear
p27Kip1 works as an anti-proliferative protein, while cyto-
plasmic p27kip1 promotes cytoskeleton remodeling that is
important for tumor cell motility and dissemination. In
particular, subcellular location of p27Kip1 is significantly
correlated with survival of breast cancer patients [29,30].
In order to verify functional competency of p27kip1 as a
cell cycle inhibitor, we analyzed cellular localization of
p27kip1 with immunocytochemistry. A substantial amount
of p27kip1 is still located in nuclear compartment of APP-
kd cells even after one hour in serum-containing medium
(Figure 2D). Conversely, in control cells, p27kip1 located in
nuclei required much longer exposure time to be displayed
owing to the substantial decrease of total protein with 10%
serum stimulation, and potentially the redistribution of
p27kip1 to cytoplasmic compartment. These results indicate
that serum-sensitive signaling pathways regulating p27kip1
expression and cytoplasmic translocation were skewed byFigure 2 APP involved in the induction of cell cycle inhibitor p27kip1
using two different shRNA constructs of APP (shAPP-5 and shAPP-7) resulte
expression. The p27kip1 expression was elevated in shAPP-5 and shAPP-7 ce
M-IV after introduction of shluc, shAPP-5, or shAPP-7. (C) The control and s
and then released with 10% serum for the indicated time points. The cells
expression. (D) The cells incubated in serum-free medium for 18 hours wer
acquired to show subcellular localization of p27kip1. The nuclear localized p
acquisition was needed to detect p27kip1 in the control (shluc) cells due toAPP knockdown. These data also suggest that APP plays a
crucial role for cell proliferation of malignant breast can-
cers by modulating the expression of cyclin-dependent
kinase inhibitor, p27kip1.
APP modulates breast cancer cell survival
The reduction of breast tumor growth may result not
only from blocking cell cycle progression but also the in-
duction of programmed cell death. Thus, we examined if
knockdown of APP expression induces cell death in
MCF10A and MDA-MB-231 cell lines. Knocking down
of APP in M-II cells significantly induced apoptotic
markers such as cleavage product of PARP and cleaved
caspase-3 in contrast to the normal immortalized M-I
cells which did not sensitively induce such apoptotic
markers. Moreover, M-III and M-IV showed such apop-
totic markers to a much greater extent (Figure 3A),
suggesting that the cell survival of advanced breast cancer
cells is more dependent on APP expression than non-in breast cancer cells. (A) Knock-down of APP in MDA-MB-231 cells
d in marked suppression of both cellular and soluble form of APP
lls. (B) The p27kip1 and p21cip1 expression was evaluated in M-I and
hAPP-7 cells were incubated in serum deprived medium for 3 hours
were harvested and subjected to assessment of p27kip1 and p21cip1
e treated with 10% serum for 60 minutes and then the images were
27kip1 was confirmed by merging with DAPI images. The longer image
the low expression of p27kip1. Scale bar = 20 μm.
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the induction of apoptotic markers in MDA-MB-231 and
the sensitivity to therapeutic agents such as recombinant
tumor necrosis factor (TNF)-related apoptosis-inducing
ligand (TRAIL), or 5-Fluorouracil (5-FU). TRAIL has been
tested as a potential therapeutic agent for various types of
cancer in clinical trials [31], and 5-FU is a conventional
chemotherapeutic agent that is commonly used for cancer
therapy [32]. The cleaved capase-3 and PARP were
augmented in MDA-MB-231 APP-kd cells (shAPP-5 or
shAPP-7) (Figure 3B) which were consistent with the
results from M-III and M-IV cells (Figure 3A). The induc-
tion of apoptosis by knockdown of APP was also con-
firmed by FACS analysis with staining for Annexin V and
propidium iodide (PI). The apoptotic cell populations with
Annexin V-high and PI-low were obviously increased in
APP-kd cells showing about 25-fold (shAPP-5) and 14-
fold (shAPP-7) induction as compared to controlFigure 3 Reduction of APP expression is associated with the apoptot
infected with lentivirus encoding control (shluc) or APP shRNA (shAPP-7) and
alteration of apoptotic indicators such as cleaved PARP and cleaved Caspase-
encoding shluc, shAPP-5, or shAPP-7. Each cell line was treated with TRAIL (10
apoptotic events were compared by staining for extracellular Annexin V and
with Annexin V high and PI low were indicated as percentage.(Figure 3C and 3D). These results clearly indicate that
APP expression on breast cancer cells is closely interelated
with cell survival.
APP affects cell growth in 3D culture and in xenografted
mouse model
In order to solidify the finding of APP functions on cell
growth, we employed three-dimensional (3D) cultures of
breast cancer cells in reconstituted basement membrane
(Matrigel, BD Bioscience). It is widely recognized that
the 3D cultures offer many microenvironmental cues
which reconstitute in vivo tumor cell behavior [33,34].
The APP-kd MDA-MB-231 cells and its counterpart
were cultured in 3D Matrigel up to 7 days. The control
MDA-MB-231 cells showed higher tumor growth than
APP-kd cells. Interestingly, control MDA-MB-231 cells
showed stellate 3D phenotype whereas APP-kd cells dis-
played more round forms (Figure 4A and 4B). Since theic induction in breast cancer cells. (A) A series of MCF-10A cells were
then tested for APP expression by immunoblotting. Under this condition,
3 were compared. (B) MDA-MB-231 cells were infected with lentivirus
ng/ml) or 5-FU (200 μM) for 24 hours. (C, D) The on-going early
cell viability with propidium iodide (PI). The apoptotic cell populations
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tional and genetic alteration of cancer cells as shown in
altered E-cadherin expression [35,36], the 3D morpho-
logical change of APP-kd cells would result in behavioral
and functional conversion. To confirm these in vitro
findings further, we examined the effect of APP in the
tumor xenograft mouse model. We injected the control
or APP-kd MDA-MB-231 cells (2x106) subcutaneously
to nude mice and maintained the mice for 6 weeks. Con-
sistent with the findings in cell culture models, APP-kd
cells showed significantly reduced tumor forming ability
in vivo compared to control (Figure 4C). As an independ-
ent experiment, we subcutaneously injected further re-
duced numbers (2.5×105) of MDA-MB-231 cells (groups
of control and APP-kd) and then measured tumor size
over time. As a result of measurement up to 28-days post
injection, there was a significant difference in tumor vol-
ume between control and APP-kd groups (Figure 4D).
Tumor growth was negligible and difficult to measure in
APP-kd group up to 22-days. These 3D culture and
in vivo xenograft studies strongly support the role of APP























































Figure 4 APP modulates breast cancer cell growth in 3D culture and in
on-top assay. The cells were seeded (2x104/well) in 48-well plate coated with
in every two days. The morphology of growing cells were obtained (A) and f
(2x106) cells were injected into nude mice s.c. (n = 6) and allowed to grow fo
compared. (Scale bar = 1cm) (D) The independent xenograft study (2.5x105 ce
cell growth rate was largely decreased as compared to control group (p < 0.0APP is engaged in IGF1-induced AKT activation
To understand the underlying mechanism of the effect of
APP on breast cancer cells, we examined the signaling
pathways potentially linked to p27kip1 and apoptotic induc-
tion in APP-kd cells. MDA-MB-231 cells are known to
possess both K-Ras and B-Raf oncogenic mutations [37]
which regulate ERK pathway. Thus, we examined the effect
of APP-kd on ERK activation. After EGF treatment, APP
knockdown failed to reduce ERK activation at both basal
and EGF-stimulated conditions of MDA-MB-231 cells
(Figure 5A). In addition, NF-κB activation, which is im-
portant for cell survival, was unaffected by APP knock-
down, as indicated by similar level of I-kB degradation and
p-p65 (Ser536) post LPS stimulation (Figure 5B), suggest-
ing both pathways are not likely responsible either for
p27kip1 or apoptotic induction in APP-kd cells. Next, we
examined IGF-1/AKT signaling pathway in APP-kd cells
since AKT/FOXO signaling axis have been identified as
critical signaling intermediates for breast cancer survival,
growth, and migration as well as therapeutic drug resist-
ance [38,39]. In the APP-kd cells, IGF-1-induced AKT





























xenografted model. MDA-MB-231 cells were subjected to 3D Matrigel
Matrigel in triplicate and then cultured for 7 days with medium change
ollowed by MTT assay (B). (C) The control and shAPP-7 MDA-MB-231
r 6 weeks. The grown tumors were excised and the grown tumor size
lls s.c injected; n = 5, respectively) revealed that shAPP-7 MDA-MB-231
1).
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phosphorylation at Ser 9 was reduced (Figure 5C). Knock
down of APP also significantly reduced the phosphoryl-
ation of FOXO, a main substrate of AKT and a transcrip-
tion factor that regulates cell cycle progression through
induction of cell cycle inhibitors including p21cip1 and
p27kip1. AKT is known to suppress FOXO family by indu-
cing phosphorylation, nuclear export, and degradation
which lead to subsequent p21cip1 and/or p27kip1 reduction
[40]. AKT can also directly phosphorylate and regulate
p27kip1 cytoplasmic redistribution [41]. As demonstrated in
Figure 2, p27kip1 remained in the nucleus for a longer time
in APP-kd cells after serum release. Thus, it is likely that
mitigated AKTactivation in APP-kd cells resulted in higher
p27kip1 expression and prolonged retention in nucleus.
Next, we examined the change of GSK3β downstream tar-
get proteins (Figure 5D). The expression of β-catenin and
its downstream targets such as survivin and CD44, but not
Cyclin D1 were affected by knockdown of APP likely
through AKT-GSK3β axis. These findings indicate thatFigure 5 APP significantly impacts IGF-1-mediated activation of AKT a
APP-kd (shAPP) cells were treated with EGF (50 ng/ml), LPS (100 ng/ml), or
assessed in the APP knock-down cells post stimulation with EGF. (B) LPS-med
cells was tested by demonstrating the level of IκBα expression and NF-κB acti
and phosphorylation of Akt target proteins such as GSK3β (S9) and FOXO1 (T
of GSK3β, and its downstream targets such as Survivin and CD44, but not Cycelevated APP expression in breast cancer may promote cell
growth and survival by the induction of AKT-FOXO and
AKT- GSK3β signaling cascades.
APP reduction reduces cell motility in MDA-MB-231 cells
Since APP expression has been linked to cell migration
[6,16], we explored the role of APP in cell migration and
invasion of MDA-MB-231. The confluent control (shLuc)
and APP-kd (shAPP-5 or shAPP-7) cell cultures were
wounded and allowed to migrate into the wounded area
in low serum containing medium with or without IGF-1.
APP-kd cells showed very limited cell migration into
the wounded space compared to the control cells in the
absence of any stimulation. Moreover, upon IGF-1 treat-
ment, more substantial difference in cell migration was
observed between control and APP-kd cells (Figure 6A).
Next, we assessed the cell migration ability of APP-kd
MDA-MB-231 cells in transwell chambers. As was ob-
served in the wound healing assay, APP-kd cells exhibited
limited migration ability with about 50% reduction innd its downstream effectors. Both MDA-MB-231 control (shluc) and
IGF-1 (100 ng/ml) as indicated. (A) EGF-mediated Erk activation was
iated activation of pro-inflammatory response in the APP knockdown
vation (phosphorylated p65 at S536). (C) IGF-1-stimulated Akt activation
24) were examined. (D) APP affects the expression of β-Catenin, a target
lin D1.
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(Figure 6B and 6C). Notably, MDA-MB-231 control cells
treated with IGF-1 showed spindle-like mesenchymal cell
morphology whereas APP-kd cells did not, suggesting the
potential role of APP during cell invasion and metastasis
through regulation of epithelial-mesenchymal transition
(EMT). Taken together, our data indicate that APP is
involved in the regulation of cell motility triggered by
IGF-1 and APP might be an attractive therapeutic target
to prevent cell invasion and metastasis.
Increased expression of APP in human breast cancer tissues
In order to examine the clinical relevance of APP
expression in breast cancer, a tissue microarray (TMA)Figure 6 APP promotes cell migration of MDA-MB-231 and its expres
The cell motility of APP knockdown (shAPP) MDA-MB-231 was examined in
or treated with IGF-1 (25 ng/ml) for 18 hours in 0.1% serum containing me
bar = 200 μm). (B) The role of APP for cell migration was evaluated in Boyden
for 18 hours. The rectangular area was further magnified for demonstration of
counted in three randomly selected areas. (D) No staining for APP (22C11) is p
grade 1 invasive ductal carcinoma shows weak staining for APP. (F) The poorly
APP. Scale bar = 100 μm.containing various grades of breast cancer tissues and
normal breast tissues was analyzed with an anti-APP
antibody (22C11). In the normal breast tissues, there
was minimal to no staining of the breast epithelium.
However, the vast majority of the invasive breast carcin-
omas showed some degree of APP expression. In total,
there were 40 invasive breast carcinomas that could be
evaluated on the TMA sections stained with 22C11 anti-
body. No staining was observed in 3 (7.5%) of the cases.
Weak staining was observed in 10 (25%) of the cases,
moderate staining in 18 (45%), and strong staining in 9
(22.5%). Though the number of cases in this series is
small, there was a trend seen where the higher grade
tumors showed more intense staining than the lowersion is elevated in invasive breast cancer of human tissues. (A)
wound healing assay. Following the wounding, cells were untreated
dium. Cells were then fixed and stained for clear demonstration (scale
chamber assay in serum-free medium with or without IGF-1 (50 ng/ml)
different cell morphology. (C) The migrated cells in panel B were
resent in this normal terminal duct lobular unit. (E) The well-differentiated
-differentiated grade 3 invasive ductal carcinoma shows strong staining for
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support our hypothesis that elevated APP expression has
close correlation with tumor cell growth and progression.
Discussion
Our data strongly indicate the pathological role of APP in
breast cancer. First, we demonstrated increased expression
APP in breast cancer cells and its correlation with malig-
nancy. Second, the inhibition of APP expression in breast
cancer cells effectively prevents cell growth and motility
in vitro and in vivo models. Third, we also demonstrated
that APP is mechanistically linked to the AKT/FOXO and
AKT/GSK3-β pathways which are known to modulate cell
growth, survival, and invasion of breast cancer cells
through the regulation of target genes including p27kip1
and survivin. Importantly, knocking down of APP expres-
sion resulted in retarded cell growth in vitro and in vivo
xenografted mouse model. We found that the slower cell
proliferation was, in part, caused by the upregulated cell
cycle inhibitor p27kip1 expression in APP-kd cells. Thus,
increased APP expression is inversely correlated with
p27kip1 expression in malignant breast cancers. Since the
reduced p27kip1 expression is correlated with tumor
aggressiveness and poor patient survival [29], this finding
suggests that APP plays a significant role in regulation of
p27kip1 in a malignant human breast cancer. In addition,
knockdown of APP in breast cancers augmented apoptotic
markers and it is likely that advanced breast cancers
(M-II, M-III, and M-IV) with knockdown of APP are
more prone to enter into apoptosis. Similarly, in addition
to the result of MCF-10A cells, APP knockdown in MDA-
MB-231 promotes sensitivity to therapeutic treatments of
TRAIL or 5-FU, implying that targeting APP in malig-
nant breast cancers may promote the sensitivity to
therapeutic drugs. Since homozygous APP-deficient
mice are viable and normal in development [42], it
seems that normal breast epithelial cell growth is not
affected by knockdown of APP expression. However,
advanced breast cancers may struggle to survive in the
absence of APP, presumably because they have evolved to
survive better, at least in part, in an APP-dependent
manner. After the submission of this manuscript,
Goodarzi et al. [43] published an article demonstrating
the biological effect of APP in the regulation of breast
cancer progression. Their results suggest that APP might
suppress aggressiveness of breast cancer cells. While those
results are not overlapped with the phenotype of our APP
knockdown experiments, both reports strongly suggest the
pathological role of APP in breast cancer pathogenesis.
The discrepancy between two studies might be explained
by different cellular conditions used in the studies. While
they examined the role of APP under the condition of
TARBP2 knockdown, our study examined a direct function
of APP in the parental MDA-MB-231 cells without anyother combinatorial genetic modifications. These results
strongly suggest that the pathological role of APP in breast
cancer pathogenesis works diversely upon the cellular
context and this needs to be addressed in the future study.
Our data also suggest that APP is involved in IGF-1/
AKT signaling pathways, which are key regulatory path-
ways for cell growth and survival of breast cancer. APP-kd
cells displayed mitigated AKT activation which leads to
decreased inhibitory phosphorylation of GSK3β (Ser9) and
FOXO1 (T24). GSK3β is known to suppress β-catenin-
dependent oncogenic signaling pathway by phosphorylating
β-Catenin [44,45]. Activation of β-catenin is reported in
subgroup of triple negative breast cancers (i.e., aggressive
breast cancers possessing lack of estrogen receptor,
progesterone receptor, and Her2 receptor expression) and
is associated with poor clinical outcomes [44]. On the other
hand, FOXO family including FOXO1 can induce cell
cycle inhibitors (e.g., p27kip1, p21cip1) and pro-apoptotic
molecules (e.g., BIM, BNIP3, FASL, TRAIL, and survivin)
[46]. The anti-apoptotic protein, survivin, is a family
member of inhibitors of apoptosis (IAP) which embodies
diverse cellular function, encompassing mitosis, metabol-
ism, and survival by promoting adaptation to stresses
[47]. As such, FOXO-survivin and β-catenin-survivin
regulatory pathways are considered to play an essential
role for the expression of survivin in breast cancer
[38,44]. Thus, our results strongly suggest that APP-
mediated regulation of AKT/FOXO and AKT/GSK3β
pathways are playing a significant role for breast cancer
development. Supporting this hypothesis, a previous
study demonstrated that sAPPα stimulates AKT/GSK3β
pathway in neuronal cells and consequently resulted in
its neuroprotective effect [48].
Interestingly, APP is also known to promote cell migra-
tion in neuronal progenitor cells [16] and engage in neur-
onal growth cone adhesion where it plays a role as an
independently operating cell adhesion molecule for bind-
ing to extracellular matrices such as laminin [6]. Acquiring
cell motility is a key aspect enabling cancer cells to invade
into adjacent tissue and disseminate into the secondary
organs. We therefore examined the cell motility and inva-
sion ability of MDA-MB-231 after knocking down of APP
expression. Upon stimulation with IGF-1 that promotes
cell migration and cancer metastasis, APP-kd cells migrate
slowly in response to IGF-1 partly due to limited activa-
tion of AKT. It is well known that AKT plays an import-
ant role in the process of EMT via repression of E-cadhrin
[49]. In addition, β-catenin is also closely engaged in EMT
and cell migration [50,51]. Our findings that APP is func-
tionally linked with AKT activation and GSK-3β/β-catenin
pathways warrant the future study that elevated APP in
malignant breast cancers is associated with dissemination
of breast cancer into other target organs by promoting
EMT process.
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In summary, we found that the expression of APP is
increased both in mouse and human malignant breast
cancer cell lines and similarly in human breast cancer
tissues. The APP expression is important to regulate cell
growth, apoptosis, and motility of breast cancer, possibly
through engagement of AKT-mediated signaling pathways.
Overall, our findings provide substantial groundwork for
the pathophysiological function of APP and its underlying
mechanism that promotes breast cancer malignancy.
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